Plant Name: Selaginella tamariscina
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; HTR2C; DRD3; | |
| TSHR; OPRD1; | |
| PTPN1; | |
| RECQL; TDP1; ADK; PKM; HSD17B1; HSD17B10; ALOX15; NOX4; USP2; TNKS2; TNKS; | |
| ACHE; | |
| CFTR; | |
| GSK3B; SYK; FLT3; CDK6; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA3; CA5B; CA5A; CA6; | |
| AR; | |
| ESR1; ESR2; | |
| MAOA; PTGS2; XDH; | |
| BACE1; | |
| MMP9; MMP1; MMP2; | |
| TP53; NFKB1; HIF1A; STAT6; | |
| SLC28A3; SLC28A2; SLC28A1; | |
| VCP; | |
| ABCG2; ABCC1; | |
| HTT; NPC1; MCL1; LMNA; MAPT; THPO; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.875E-11 | 4.575E-08 | ADORA2A, CA2, CA7, CFTR, DRD3, HIF1A, HTT, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.219E-10 | 1.475E-07 | ADORA1, ADORA2A, CA2, CA7, CDK6, CFTR, DRD3, HIF1A, HTR2C, HTT, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.210E-10 | 4.167E-07 | AR, CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, MMP1, MMP2, MMP9, PTPN1, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.326E-08 | 6.875E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.729E-08 | 8.754E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.380E-08 | 1.542E-05 | ABCG2, ACHE, ADORA2A, CSNK2A1, ESR1, ESR2, FLT3, HTT, MAPT, MCL1, MMP9, NFKB1, PKM, PTGS2, SMN1, SMN2, STAT6, TP53, TTR, USP2, VCP, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.032E-07 | 1.171E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.207E-07 | 1.431E-04 | AR, CFTR, CYP1A1, CYP1B1, ESR1, FLT3, NFKB1, NOX4, NPC1, PTGS2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 6.812E-07 | 1.766E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 8.396E-07 | 2.078E-04 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2, VCP |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.579E-06 | 3.404E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.815E-06 | 3.764E-04 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
| BP | GO:0065007; biological regulation | GO:0044093; positive regulation of molecular function | 2.357E-06 | 4.615E-04 | ADORA1, AR, CFTR, ESR1, ESR2, FLT3, GSK3B, HIF1A, HTT, MAPT, MMP9, NFKB1, NOX4, OPRD1, PTPN1, SYK, TNKS, TSHR, VCP, XDH |
| BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 2.858E-06 | 5.365E-04 | ADORA2A, AR, CFTR, CSNK2A1, DRD3, GSK3B, HIF1A, HTT, LMNA, MAPT, PTGS2, PTPN1, SYK, TP53 |
| BP | GO:0065007; biological regulation | GO:0050790; regulation of catalytic activity | 3.339E-06 | 6.060E-04 | ADORA1, ADORA2A, ADORA3, AR, CSNK2A1, DRD3, ESR1, FLT3, GSK3B, HIF1A, HTT, MAPT, MMP9, NFKB1, NOX4, PTGS2, PTPN1, SYK, TNKS, TP53, TSHR, VCP, XDH |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.769E-06 | 6.566E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 5.371E-06 | 8.727E-04 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.371E-06 | 8.727E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 7.366E-06 | 1.146E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 7.366E-06 | 1.146E-03 | GSK3B, HTT, MAPT |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.024E-05 | 1.571E-03 | ADORA1, ADORA2A, CA2, CA7, DRD3, HTR2C, HTT |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.270E-05 | 1.831E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 1.295E-05 | 1.831E-03 | SLC28A2, SLC28A3 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.295E-05 | 1.831E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.295E-05 | 1.831E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 1.295E-05 | 1.831E-03 | SLC28A2, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 1.469E-05 | 2.012E-03 | ADORA1, ALOX15, AR, FLT3, HTR2C, NOX4, PTPN1, SYK, THPO, XDH |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.544E-05 | 2.101E-03 | AR, CDK6, CSNK2A1, DRD3, ESR1, FLT3, HIF1A, MMP2, MMP9, PTGS2, SYK, THPO, TSHR |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.704E-05 | 2.277E-03 | ALOX15, ESR1, GSK3B, MAPT, MMP1, TP53, VCP |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.853E-05 | 2.431E-03 | ABCG2, CA12, CA2, CA7, CFTR, DRD3, ESR1, HIF1A, HTR2C, HTT, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.871E-05 | 2.440E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.433E-05 | 2.976E-03 | HIF1A, MCL1, MMP9, PTGS2, PTPN1 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 2.468E-05 | 3.002E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.765E-05 | 4.219E-03 | HIF1A, LMNA, OPRD1, PTGS2, TP53 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 3.875E-05 | 4.219E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.875E-05 | 4.219E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 3.875E-05 | 4.219E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.875E-05 | 4.219E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.875E-05 | 4.219E-03 | CYP1A1, CYP3A4 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.875E-05 | 4.219E-03 | ADORA1, ADORA2A |
| BP | GO:0032501; multicellular organismal process | GO:0045187; regulation of circadian sleep/wake cycle, sleep | 4.237E-05 | 4.539E-03 | ADORA1, ADORA2A, DRD3 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 4.252E-05 | 4.539E-03 | ADORA1, ADORA2A, ADORA3, AR, CDK6, CYP1B1, LMNA, NOX4, PTGS2, TP53, XDH |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 4.671E-05 | 4.890E-03 | ADORA2A, DRD3, HTR2C, NPC1, OPRD1, USP2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.785E-05 | 5.778E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 6.562E-05 | 6.466E-03 | ADORA2A, ADORA3, CSNK2A1, CYP1B1, DRD3, ESR1, GSK3B, MAPT, MMP9, NFKB1, PTGS2, PTPN1, TNKS, TP53 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 7.171E-05 | 6.971E-03 | CDK6, CFTR, CYP1B1, NFKB1, PTGS2, STAT6, TP53 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 7.461E-05 | 7.191E-03 | CYP1B1, NFKB1, OPRD1, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.663E-05 | 7.191E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 7.731E-05 | 7.191E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.731E-05 | 7.191E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.731E-05 | 7.191E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.731E-05 | 7.191E-03 | CYP1A2, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 7.851E-05 | 7.244E-03 | ADORA3, AR, CYP1B1, ESR1, ESR2, NFKB1, OPRD1, SYK |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 8.528E-05 | 7.802E-03 | ADORA2A, MAPT, OPRD1, VCP |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.116E-04 | 9.762E-03 | CDK6, GSK3B, HIF1A, MAPT, MCL1, PTGS2, PTPN1, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.116E-04 | 9.762E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 1.124E-04 | 9.792E-03 | ACHE, ADORA1, BACE1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, GSK3B, HSD17B10, MAOA, PKM, TP53, USP2, VCP, XDH |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.909E-22 | 1.287E-17 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.336E-18 | 4.721E-14 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.506E-15 | 2.398E-11 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.688E-21 | 4.355E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.243E-07 | 6.714E-06 | AR; GSK3B; CDK6; FLT3; MMP1; MMP2; PTGS2; HIF1A; TP53; MMP9; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.180E-08 | 4.196E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.516E-07 | 3.449E-05 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.943E-06 | 1.278E-04 | OPRD1; ABCC1; ADORA3; ADORA1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.146E-06 | 2.274E-04 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; MMP9; NFKB1; MCL1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.143E-05 | 2.274E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.006E-05 | 2.274E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.264E-05 | 2.274E-04 | MMP1; MMP2; MMP9; TP53 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.158E-05 | 8.356E-04 | OPRD1; ADORA2A; ADORA3; ADORA1; HTR2C; DRD3; TSHR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.930E-05 | 1.264E-03 | PKM; FLT3; TP53; HIF1A |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.147E-04 | 1.264E-03 | GSK3B; CDK6; CSNK2A1; TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.183E-04 | 1.264E-03 | GSK3B; ESR1; NFKB1; ESR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.600E-04 | 1.440E-03 | CDK6; STAT6; TP53; MMP9; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.120E-04 | 1.264E-03 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.248E-04 | 1.264E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.685E-04 | 2.175E-03 | GSK3B; AR; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.354E-04 | 2.007E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.032E-04 | 2.969E-03 | MMP2; ESR1; MMP9; ESR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.646E-04 | 4.306E-03 | ADORA2A; ADORA1; CFTR; NFKB1; TSHR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.270E-04 | 4.362E-03 | MMP2; TP53; HIF1A; ESR1; MMP9 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.177E-04 | 2.451E-03 | SYK; CSNK2A1; PTGS2; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 7.110E-04 | 4.362E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.598E-04 | 4.368E-03 | CDK6; PKM; SYK; TP53; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.429E-04 | 4.306E-03 | MAOA; ALOX15; HTR2C; PTGS2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.138E-03 | 5.947E-03 | PKM; MAOA; HSD17B1; CYP1A2; ALOX15; CYP1A1; ADK; PTGS2; CYP3A4; CYP19A1; HSD17B10; XDH |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.232E-03 | 6.237E-03 | GSK3B; CDK6; SYK; TP53; NFKB1; MCL1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.820E-04 | 4.368E-03 | GSK3B; TP53; ESR1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.475E-03 | 7.239E-03 | LMNA; TP53; NFKB1; MCL1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.406E-04 | 1.339E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.966E-04 | 5.381E-03 | ADORA1; PTGS2; TSHR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.863E-03 | 1.189E-02 | BACE1; GSK3B; MAPT; HSD17B10 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 4.906E-04 | 3.456E-03 | ABCC1; CFTR; ABCG2 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.605E-03 | 7.427E-03 | CDK6; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.143E-03 | 9.137E-03 | CDK6; TP53; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.665E-03 | 1.484E-02 | FLT3; TP53; MMP9; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.143E-03 | 9.137E-03 | GSK3B; SYK; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.535E-03 | 7.316E-03 | CYP1A2; CYP1A1; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.783E-03 | 2.616E-02 | PTGS2; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.614E-03 | 2.614E-02 | PTPN1; GSK3B; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.823E-03 | 8.206E-03 | MAOA; CYP1A2; CYP3A4 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.611E-03 | 3.244E-02 | GSK3B; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.048E-02 | 3.773E-02 | GSK3B; MAOA; DRD3 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 9.415E-03 | 3.466E-02 | GSK3B; CDK6; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.138E-02 | 3.923E-02 | GSK3B; TP53; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.357E-02 | 4.485E-02 | GSK3B; CSNK2A1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.430E-02 | 4.635E-02 | GSK3B; TP53 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.591E-02 | 4.957E-02 | VCP; NFKB1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.277E-02 | 4.311E-02 | MAOA; NFKB1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.591E-02 | 4.957E-02 | GSK3B; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.132E-02 | 3.923E-02 | CYP3A4; XDH |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.199E-04 | 1.264E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; DRD3 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; ADORA2A; ADORA1; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; PTGS2; PTGS2; ABCC1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ADORA1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA3; ADORA2A; ADORA1; CA1; CA1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA2A; ADORA1; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ADORA2A; OPRD1; ADK; ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PKM; HTR2C |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HTR2C; HTR2C |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | VCP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; MAPT |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; ADORA1; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; HTR2C |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; MAOA; MAOA; HTR2C; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; TP53; FLT3; CA9; MMP9; MMP2; HIF1A; PKM |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; HTR2C |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; MMP1; OPRD1; PTGS2; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1; MAOA; PTGS2; PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; OPRD1; CYP3A4; MAOA; HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; MAOA; HTR2C |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; ACHE; ADORA3; SYK; TP53; CA1; FLT3; FLT3; CA9; MMP9; ESR1; ESR1; MMP2; NFKB1; PTGS2; HIF1A; MCL1; CSNK2A1 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; ADORA1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; HTR2C |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; MMP2 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| NA: NA | Primary insomnia | NA | HTR2C |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |